Table of Contents
Lung Cancer International
Volume 2017, Article ID 9614938, 5 pages
https://doi.org/10.1155/2017/9614938
Research Article

Impact of Cytological Sampling on EGFR Mutation Testing in Stage III-IV Lung Adenocarcinoma

1Velindre Cancer Centre, Cardiff, UK
2Institute of Medical Genetics, University Hospital of Wales, Cardiff, UK
3University Hospital Llandough, Cardiff, UK

Correspondence should be addressed to Rhian Siân Davies; moc.liamg@naisnaihr

Received 9 November 2016; Revised 16 February 2017; Accepted 20 February 2017; Published 7 March 2017

Academic Editor: Giovanni Luca Ceresoli

Copyright © 2017 Rhian Siân Davies et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, E. Steliarova-Foucher, J. Lortet-Tieulent et al., “Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012,” European Journal of Cancer, vol. 49, no. 6, pp. 1374–1403, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. D. E. Gerber, L. Gandhi, and D. B. Costa, “Management and future directions in non-small cell lung cancer with known activating mutations,” American Society of Clinical Oncology Educational Book, pp. e353–e365, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. L. V. Sequist, J. C.-H. Yang, N. Yamamoto et al., “Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations,” Journal of Clinical Oncology, vol. 31, no. 27, pp. 3327–3334, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. Y.-L. Wu, C. Zhou, C.-P. Hu et al., “Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFRmutations (LUX-Lung 6): an open-label, randomised phase 3 trial,” The Lancet Oncology, vol. 15, no. 2, pp. 213–222, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. T. S. Mok, Y. Wu, S. Thongprasert et al., “Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma,” The New England Journal of Medicine, vol. 361, no. 10, pp. 947–957, 2009. View at Publisher · View at Google Scholar
  6. A. T. Shaw, D.-W. Kim, K. Nakagawa et al., “Crizotinib versus chemotherapy in advanced ALK-positive lung cancer,” The New England Journal of Medicine, vol. 368, no. 25, pp. 2385–2394, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. NICE, NICE Clinical Guideline 121: The Diagnosis and Treatment of Lung Cancer, NICE, 2011.
  8. G. Da Cunha Santos and M. A. Saieg, “Preanalytic parameters in epidermal growth factor receptor mutation testing for non-small cell lung carcinoma: a review of cytologic series,” Cancer Cytopathology, vol. 123, no. 11, pp. 633–643, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. R. J. José, P. Shaw, M. Taylor et al., “Impact of EBUS-TBNA on modalities for tissue acquisition in patients with lung cancer,” QJM, vol. 107, no. 3, pp. 201–206, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Jurado, A. Saqi, R. Maxfield et al., “The efficacy of EBUS-guided transbronchial needle aspiration for molecular testing in lung adenocarcinoma,” Annals of Thoracic Surgery, vol. 96, no. 4, pp. 1196–1202, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Ellison, G. Zhu, A. Moulis, S. Dearden, G. Speake, and R. McCormack, “EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples,” Journal of Clinical Pathology, vol. 66, no. 2, pp. 79–89, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. A. S. Albanna, G. Kasymjanova, C. Robitaille et al., “Comparison of the yield of different diagnostic procedures for cellular differentiation and genetic profiling of non-small-cell lung cancer,” Journal of Thoracic Oncology, vol. 9, no. 8, pp. 1120–1125, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. N. I. Lindeman, P. T. Cagle, M. B. Beasley et al., “Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology,” Journal of Thoracic Oncology, vol. 8, no. 7, pp. 823–859, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Scarpino, F. Pulcini, A. Di Napoli, M. Giubettini, and L. Ruco, “EGFR mutation testing in pulmonary adenocarcinoma: evaluation of tumor cell number and tumor percent in paraffin sections of 120 small biopsies,” Lung Cancer, vol. 87, no. 1, pp. 8–13, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Inoue, K. Kobayashi, K. Usui et al., “First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy,” Journal of Clinical Oncology, vol. 27, no. 9, pp. 1394–1400, 2009. View at Publisher · View at Google Scholar
  16. C. J. Langer, “The ‘Lazarus Response’ in treatment-naïve, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation,” Journal of Clinical Oncology, vol. 27, no. 9, pp. 1350–1354, 2009. View at Publisher · View at Google Scholar · View at Scopus